I some what agree with the whole production capability concerns...

I some what agree with the whole production capability concerns for AT1, especially when I look at LDX who now have capacity to produce 10million tests per month (~120M pa.) when compared to AT1's 1.3m a month (~15M pa.). But a few considerations that have already been pointed out:

- AT1 don't manufacture RAT supply constraints from Access Bio unlikely as they have HUGE capacity in manufacturing of this device; and
- Yes AT1's manufacturing of antibody test is low, but I don't see competing levels of demand for this test when comparing to RAT.

What I can't comprehend yet is why LDX will continue to use AT1 as the supplier of its FebriDx device once they get FDA approval. Especially if AT1 production capacity can't keep up with demand for the product derived from the US market. Alternatively, will LDX utilise their own manufacturing capabilities to produce the test under contract with AT1?